Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Academic Article uri icon

start page

  • 97

end page

  • 105

abstract

  • Neurocognitive deficits are severe in first-episode psychosis.Patients (N = 263) with first-episode psychosis (schizophrenia, schizoaffective, or schizophreniform disorders) were randomly assigned to double-blind treatment with olanzapine (mean 11.30 mg/day) or haloperidol (mean 4.87 mg/day) for 104 weeks. A neurocognitive battery was administered at baseline (n = 246) and 12 (n = 167), 24 (n = 126), 52 (n = 89), and 104 (n = 46) weeks during treatment. Weighted principal component and unweighted composite scores were derived from individual tests.Both treatment groups demonstrated significant improvement on both composite scores. On the basis of the weighted composite score, olanzapine had greater improvement than haloperidol only at 12 (p = .014) and 24 (p = .029) weeks. For the unweighted composite, olanzapine had significantly better improvement compared with haloperidol only at week 12 (p = .044). At week 12 only, olanzapine improved performance on the Digit Symbol and Continuous Performance Test significantly more than haloperidol.Both antipsychotic agents appeared to improve neurocognitive functioning among first-episode psychosis patients with schizophrenia. A significantly greater benefit in terms of neurocognitive improvement was found with olanzapine than with haloperidol at weeks 12 and 24.

date/time value

  • January 2006

Digital Object Identifier (DOI)

  • 10.1016/j.biopsych.2005.06.022

PubMed Identifier

  • 16140282

volume

  • 59

number

  • 2

keywords

  • Adult
  • Antipsychotic Agents
  • Benzodiazepines
  • Cognition Disorders
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Haloperidol
  • Humans
  • Male
  • Neuropsychological Tests
  • Principal Component Analysis
  • Psychotic Disorders
  • Statistics, Nonparametric